Discovery of novel DPP IV inhibitors: Application of pharmacophore-based virtual screening

Medicinal Chemistry Research

Volumn 22, Issue 2, 2013, Pages 558-572

  Sharma, Jyoti ^a   Yadav, Divya ^a   Paliwal, Sarvesh ^a  

^a BANASTHALI UNIVERSITY   (India)

Author keywords

3D quantitative structure activity relationship; Dipeptidyl peptidase IV (DPP IV); Glucagon like peptide; National Cancer Institute (NCI)

Indexed keywords

AW 01077; CD 01797; CD 02493; CD 06202; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; NSC 2450; NSC 5815; NSC 997; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG CONFORMATION; DRUG SCREENING; GLUCOSE TOLERANCE; HYDROGEN BOND; HYDROPHOBICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOPHORE; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 84874000349     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-012-0044-8     Document Type: Article

References (16)

1. Ahren B, Holst JJ, Martensson H, Balkan B (2000) Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV. Eur J Pharmacol 404:239-245
2. Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X (1999) Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 42:1324-1331
3. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M (1983) CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J Comput Chem 4:187-217
4. Deacon CF, Hughes TE, Holst JJ (1998) Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon like peptide 1 in the anesthetized pig. Diabetes 47:764-769
5. Holst JJ (1994) Glucagon-like peptide-1 (GLP-1) a newly discovered GI hormone. Gastroenterology 107:1048-1055
6. Holst JJ, Deacon CF (1998) Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 47:1663-1670
7. Jacotot E, Callebaut C, Blanco J, Krust B, Neubert K, Barth A, Hovanessian AG (1996) Dipeptidyl-peptidase IV-B, a novel form of cell-surface-expressed protein with dipeptidyl-peptidase IV activity. Eur J Biochem 239:248-258
8. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, Ribel U, Wantanabe T, Drucker DJ, Wagtmann N (2000) Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 97:6864-6879
9. Mentlein R (1999) Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85:9-24
10. Mentlein R, Gallwitz B, Schmidt WE (1993) Dipeptidylpeptidase IV hydrolyzes gastric inhibitory polypeptide, glucagon like peptide-1 (7-36), peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829-835
11. 1 receptor antagonists. Med Chem Res. doi: 10.1007/s00044-011-9756-4
12. Pederson RP, White HA, Schlenzig D, Pauly RP, McIntosh CRP, Demuth HU (1998) Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 47:1253-1258
13. Rachman J, Borrow BA, Levy JC, Turner RC (1997) Near normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide 1 (GLP-1) in subjects with NIDDM. Diabetologia 40:205-211
14. Wettergren A, Schjoldager B, Martensen PE, Myhre J, Christiansen J, Holst JJ (1993) Truncated GLP-1 (proglucagon 72-107 amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38:665-673
15. Yaron A, Nadier F (1993) Proline-dependent structural and biological properties of peptides and proteins. Crit Rev Biochem Mol Biol 28:31-81
16. Zhonghua P, Xiaofeng L, Kenton L, Thomas WG, Paul EW, Thomas HL, Bradley AZ, Kent S, Stephen JB, Michael AS, Amanda KM, David WAB, Michelle L, Heidi W, Anita JKG, David JM, Todd SM, Lakshmi B, Michael GF, Daisy P, Larry RS, Marc RL, Rohinton E, Elizabeth HF, Hing LS, James MT (2006) Discovery, structure-activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitors. J Med Chem 49:3520-3535